Table 1 Types of thrombosis and bleeding, by MPN phenotypes.

From: Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

 

Total

ET

PV

MF

Pre-PMF

p-value

 

N = 162

N = 48

N = 42

N = 56

N = 16

 

Thrombosis

Pts with thrombosis, n (%)

14 (8.6%)

8 (16.7%)

2 (4.8%)

3 (5.4%)

1 (6.3%)

0.13

N thrombosis, n (%)

15 (10.0%)

9 (18.8%)

2 (4.8%)

3 (5.4%)

1 (6.3%)

0.35

Arterial, n (%)

3 (1.9%)

1 (2.1%)

0 (0.0%)

1 (1.8%)

1 (6.3%)

0.47

 AMI

1

0

 

1

0

 

 Stroke

1

1

 

0

0

 

 PAT

1

0

 

0

1

 

Venous, n (%)

12 (7.4%)

8 (16.7%)

2 (4.8%)

2 (3.6%)

0 (0.0%)

0.031

 PEa

10

6

2

2

  

 DVT+PEa

1

1

0

0

  

 SVT

1

1

0

0

  

Time to any thrombosis, days, median (IQR)

11.5 (4.0–25.0)

7.0 (2.5–11.5)

8.0 (1.0–15.0)

25.0 (16.0–32.0)

28.0 (28.0–28.0)

0.27

Time to PE, days, median (IQR)

8.0 (0.0–14.0)

4.0 (0.0–8.0)

7.0 (0.0–14.0)

27.5 (24.0–31.0)

 

0.097

Bleeding

Pts with bleeding, n (%)

7 (4.3%)

1 (2.1%)

2 (4.9%)

4 (7.1%)

0 (0.0%)

0.51

Sites

     

0.20

 Gastrointestinal

3

0

0

3

  

 Muscle

2

1

1

0

  

 Hemoptysis

2

0

1

1

  

Trasfusion need, n (%)

5 (3.1%)

1 (2.1%)

0 (0.0%)

4 (7.1%)

 

0.030

Time to bleeding, days, median (IQR)

16.0 (13.0–24.0)

14.0 (14.0–14.0)

23.0 (16.0–30.0)

17.5 (6.5–23.0)

 

0.50

  1. ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis, pre-PMF prefibrotic myelofibrosis, Pts patients, AMI acute myocardial infarction, PAT pheripheral arterial thrombosis, PE pulmonary embolism, DVT deep vein thrombosis of the legs, SVT superficial vein thrombosis, IQR interquartile range.
  2. aPE diagnosis confirmed by imaging n = 8, not confirmed n = 3.
Back to article page